Vas Narasimhan. Novartis CEO
“We believe fundamentally that all […] Alzheimer’s trials in the industry are intervening too late. By the time you’ve seen any real symptoms, you’re actually quite far along.”
World Economic Survey
…87% of people would take a test able to predict Alzheimer before onset of symptoms even without an available treatment..
Prof. Reisa Sperling, Harvard University
On how to make Alzheimer’s trials work: “..when you’re going after this amyloid plaque buildup you need to start 10 years before”
Patient’s experience; Voices of Alzheimer’s Disease – Alzheimer’s association; 2008
“My diagnosis took eight months. […] I went through a battery – neuropsych testing, spinal taps, MRIs, blood work – you name it and I went through it.”
Voices of Alzheimer’s Disease – Alzheimer’s association; 2008
“In this bright age of science, we still don’t have a defining way of making a diagnosis early that says, This is Alzheimer’s, and let’s cope with it.”
is to enable prediction, monitoring, diagnosis & successful drug development for Alzheimer’s disease.
Diadem is determined to solve one of the biggest problems in Alzheimer’s disease drug development and patient care: early, accurate, predictive, fast, non-invasive and cost effective diagnosis.
was founded in 2012 as a spin-off of University of Brescia (Italy).
Diadem is a pure diagnostic company committed to carry on specific research and development on early peripheral markers of Alzheimer’s disease into technology, bringing together some of the most senior experts from industry and academia to advance a breakthrough in Alzheimer’s disease in the clinic. Diadem is preparing for large retrospective and prospective trials to confirm initial data
is an innovative blood-based test exploiting a proprietary antibody targeting a specific conformation of p53 protein.
This biomarker, known to be associated with several patients’ inflammatory conditions, showed instead to be highly specific for Alzheimer’s Disease onset, providing a signal also in pre-symptomatic population.
Such a test has shown in pilot clinical studies the ability to predict the risk of cognitive decline in elderly patients (symptomatic and asymptomatic) who are being assessed for Alzheimer’s Disease.
Besides providing a fast and affordable diagnosis, AlzoSure™ is an enabler of effective patient’s recruitment in clinical trials for the development of AD drugs
Our test is a plasma-based and capable of identifying a particular status of P53 which demonstrated to be highly sensitive and specific for Alzheimer’s Disease. Alzosure also proved to be accurate for beta amyloid (ẞ Amyloid PET), the standard of care biomarker in diagnosis of Alzheimer’s disease